Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 2/20 | 0.40 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9284510 | 1.00 | ACACB (0.42) | ACACBTRPA1EPHX1SIGMAR1MEN1 | |
| SCHEMBL13643094 | 0.83 | ACACB (0.41) | ACACBTRPA1EPHX1SIGMAR1MEN1 | |
| SCHEMBL5728691 | 0.83 | ACACB (0.41) | ACACBTRPA1EPHX1SIGMAR1MEN1 | |
| SCHEMBL4056413 | 0.83 | TRPA1 (0.42) | TRPA1TAAR1 | |
| SCHEMBL114824 | 0.82 | PTGS1 (0.48) | TRPA1EPHX1 | |
| SCHEMBL12197642 | 0.80 | TRPA1 (0.44) | ACACBTRPA1TAAR1 | |
| SCHEMBL8293621 | 0.80 | TRPA1 (0.44) | ACACBTRPA1TAAR1 | |
| SCHEMBL358607 | 0.80 | TAAR1 (0.59) | TRPA1MEN1KMT2ATAAR1 | |
| SCHEMBL8056894 | 0.80 | TAAR1 (0.59) | TRPA1MEN1KMT2ATAAR1 | |
| SCHEMBL10206049 | 0.80 | TRPA1 (0.44) | ACACBTRPA1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2976340-A1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-01-27 | — | — | EP | disclosed |
| WO-2014146490-A1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-09-25 | — | — | WO | disclosed |
| EP-2780014-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8772507-B2 | Imidazole-benzamide anti-cancer agents | CYTOKINETICS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| WO-2013075083-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2013-05-23 | — | — | WO | disclosed |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | QIAN XIANGPING (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-11-08 | — | — | US | disclosed |
| EP-2485591-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | Merck Sharp & Dohme Corp. (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044187-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | SCHERING CORPORATION (US) | 2011-04-14 | — | — | WO | disclosed |
| EP-1537074-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2005-06-08 | — | — | EP | disclosed |
| EP-0768305-A1 | N-Isoxazolyl-biphenylsulfonamide derivatives, their preparation and their use as endothelin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-04-16 | — | — | EP | disclosed |
| WO-1996040681-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1996-12-19 | — | — | WO | disclosed |
| EP-0411150-B1 | INDOLE DERIVATIVES, PREPARATION THEREOF, AND DRUG FOR PREVENTING AND TREATING NEPHRITIS CONTAINING SAME | OTSUKA PHARMA CO LTD (JP) | 1996-11-27 | — | — | EP | disclosed |
| EP-0682663-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-22 | — | — | EP | disclosed |
| US-5459142-A | Autoimmune disease, atherosclerosis, antiischemic agents and nephritis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-10-17 | — | — | US | disclosed |
| EP-0511879-B1 | Pyrazine derivatives | OTSUKA PHARMA CO LTD (JP) | 1995-03-22 | — | — | EP | disclosed |
| US-5380848-A | 8-azabicyclo(3.2.1)octanes | RESEARCH TRIANGLE INSTITUTE (US) | 1995-01-10 | — | — | US | disclosed |
| US-5238938-A | Nephrosis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-24 | — | — | US | disclosed |
| EP-0511879-A1 | Pyrazine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-04 | — | — | EP | disclosed |
| EP-0411150-A1 | INDOLE DERIVATIVES, PREPARATION THEREOF, AND DRUG FOR PREVENTING AND TREATING NEPHRITIS CONTAINING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | KIF5B, KIF2C, PLK1 | ACACB 903/4885TRPA1 4529/4885EPHX1 2410/4885 |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | KIF5B, KIF2C, PLK1 | ACACB 621/4885TRPA1 4628/4885EPHX1 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.